Back in 2016, shortly after Pascal Soriot had seen off a $100bn hostile takeover bid from US pharmaceuticals giant Pfizer, it was revealed that the urbane AstraZeneca boss had a surprising history of street-fighting. “I haven’t had a fight in the last 40 years,” he told the Financial Times. But growing up in the gritty suburbs north of Paris in the 1970s, they’d been a common occurrence. “The first 14, 16 years? I had one probably every week.”
Doing the decent thing
If fending off Pfizer required the pugnacity of “a bare-knuckle fighter”, Soriot has needed some rather different skills to navigate the current vaccine wars. His situation is unenviable. Having done the decent thing by rolling out the Oxford jab on a non-profit basis during the pandemic, AstraZeneca has become piggy-in-the-middle of an increasingly bitter supply row between Britain and the EU. Despite a spate of scare stories on the continent about the vaccine’s safety and efficacy, Brussels is furious that the Anglo-Swedish pharma has fallen so far short on its contracted delivery schedule. On the latest count, AstraZeneca will fall roughly ten million short of its target to deliver 40 million doses by the end of March – a goal already well below the original supply schedule of at least 100 million. Rubbing salt in the wound, officials claim the company has shipped vaccines produced in the EU to the UK, but has so far sent nothing in the opposite direction.
Soriot, 61, left France decades ago to lay down roots in Australia. But, with feelings running so high, if he hasn’t already been dubbed a “traître”, he might expect to be soon. Even leaving aside questions of national politics, his leadership is under scrutiny because of contract management and logistics cock-ups relating to the vaccine. “Charity is a good way to gain kudos,” says Breakingviews. But “future damaged relations with Europe”, a key customer for AstraZeneca’s drugs and treatments, have made investors anxious. Soriot has done a brilliant job saving AstraZeneca from the corporate scrapheap and taking it “from strength to strength” as an innovator, noted The Daily Telegraph last year, when, after “a storming few years”, the reinvigorated pharma became the most valuable company on the FTSE 100. But, despite its formidable portfolio of blockbuster drugs, its shares have been in broad decline this year.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Born in 1959, the son of a tax collector, Soriot studied medicine at France’s National Veterinary School. “I didn’t have a clue about business,” he later told the Financial Times, but when he “tired of equestrian stables” he decided going to business school would open new horizons. After graduating, he joined Roussel Uclaf, then a big French drugmaker, and took a post in Australia, later joining the Franco-German drugmaker Aventis, in the midst of its messy merger with Sanofi. When Soriot jumped ship again to Roche, he was sent to California to integrate its acquisition of Genentech. The experience was formative. Soriot particularly admired the Californian biotech’s culture of “casual intensity” – informality combined with hard work – an ethos he later built upon at AstraZeneca.
A difficult year for the hero and Daisy
Soriot has won plaudits for transforming AstraZeneca into a pioneering force and putting global health above profit in the war against Covid-19. But his halo is beginning to slip. Some commentators have sniped at the “vaccine hero’s” generous pay packet. Others are suspicious of his attempts to empire-build, most recently with the £39bn acquisition of the US rare-disease biotech Alexion. Still, having spent much of last year separated from his family, working in Switzerland, the UK or America, “often with just his cat, Daisy, for company”, Soriot has had a tough pandemic personally, notes The Times. “I can’t remember in my entire career working as hard as 2020,” he says. He can expect little respite this year.
-
‘Sandwich generation’ carers losing £6,000 a year to support elderly relativesMiddle-aged adults are often caught between caring for children or grandchildren and their elderly parents, leaving them taking time out of the workforce and facing a huge hit to wages while they are still trying to save for retirement. We look at the true cost of caring.
-
Ground rents to be capped at £250 a year – what does it mean for you?The government has published draft legislation which would see ground rents capped at £250 per year for leaseholders. We examine what it means for homeowners and the housing market.
-
Michael Moritz: the richest Welshman to walk the EarthMichael Moritz started out as a journalist before catching the eye of a Silicon Valley titan. He finds Donald Trump to be “an absurd buffoon”
-
David Zaslav, Hollywood’s anti-hero dealmakerWarner Bros’ boss David Zaslav is embroiled in a fight over the future of the studio that he took control of in 2022. There are many plot twists yet to come
-
The rise and fall of Nicolás Maduro, Venezuela's ruthless dictatorNicolás Maduro is known for getting what he wants out of any situation. That might be a challenge now
-
The political economy of Clarkson’s FarmOpinion Clarkson’s Farm is an amusing TV show that proves to be an insightful portrayal of political and economic life, says Stuart Watkins
-
The most influential people of 2025Here are the most influential people of 2025, from New York's mayor-elect Zohran Mamdani to Japan’s Iron Lady Sanae Takaichi
-
Luana Lopes Lara: The ballerina who made a billion from prediction marketsLuana Lopes Lara trained at the Bolshoi, but hung up her ballet shoes when she had the idea of setting up a business in the prediction markets. That paid off
-
Who is Christopher Harborne, crypto billionaire and Reform UK’s new mega-donor?Christopher Harborne came into the spotlight when it emerged he had given £9 million to Nigel Farage's Reform UK. How did he make his millions?
-
Why Trustpilot is a stock to watch for exposure to the e-commerce marketTrustpilot has built a defensible position in one of the most critical areas of the internet: the infrastructure of trust, says Jamie Ward
